LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 2.05 -0.03 (-1.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 1.95▼ 2.1250-Day Range 1.55▼ 2.5052-Week Range 1.06▼ 12.85Volume1.13 million shsAverage Volume4.77 million shsMarket Capitalization£16.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Shield Therapeutics alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Shield Therapeutics Stock (LON:STX)Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.Read More STX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STX Stock News HeadlinesJuly 26 at 6:18 AM | americanbankingnews.comShield Therapeutics (LON:STX) Stock Price Up 55.9%July 25 at 5:48 AM | americanbankingnews.comShield Therapeutics (LON:STX) Shares Down 13.6% July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 10:32 AM | msn.comBoss of drugs firm Shield Therapeutics steps down as US prescriptions ramp upJuly 24 at 10:32 AM | markets.businessinsider.comShield Therapeutics CEO Greg Madison To Step DownMay 28, 2024 | msn.comKorean market is latest play for Shield Therapeutics' iron deficiency drugMay 9, 2024 | finance.yahoo.comInsider Traders Lose US$91k As Shield Therapeutics DropsMay 3, 2024 | msn.comGalera Therapeutics Implements Stockholder Rights Plan to Shield Investor InterestsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 2, 2024 | msn.comTurning a tumor's 'shield' into a weapon against itselfApril 10, 2024 | msn.comNeutral Switzerland joins European Sky Shield defence projectApril 1, 2024 | tmcnet.comAmerican Home Shield Offering 40% Off ShieldGold™ For Limited TimeMarch 29, 2024 | msn.comA Real Life Invisibility Shield for Privacy in Public PlacesMarch 11, 2024 | tmcnet.comSeal Shield to Showcase Shyld AI, the World's First Intelligent, Autonomous, UV-C Disinfection System at HIMSS 2024February 23, 2024 | lse.co.ukLONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutesFebruary 22, 2024 | morningstar.comShield Therapeutics PLC STXFebruary 13, 2024 | uk.finance.yahoo.comShield Therapeutics plc (STX.L)January 24, 2024 | finance.yahoo.comShield Therapeutics (LON:STX) shareholders have endured a 89% loss from investing in the stock three years agoSee More Headlines Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:STX CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.12) Trailing P/E RatioN/A Forward P/E Ratio56.42 P/E GrowthN/ANet Income£-48,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-146.62% Return on Assets-42.79% Debt Debt-to-Equity Ratio21.30 Current Ratio2.95 Quick Ratio2.16 Sales & Book Value Annual Sales£7.40 million Price / Sales2.17 Cash FlowGBX 0.32 per share Price / Cash Flow6.36 Book ValueGBX 4 per share Price / Book0.51Miscellaneous Outstanding Shares782,060,000Free FloatN/AMarket Cap£16.03 million OptionableNot Optionable Beta0.90 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gregory P. Madison (Age 57)CEO & Executive Director Comp: $678kDr. Christian Schweiger M.D. (Age 58)Ph.D., Co-Founder & Non Executive Director Comp: $45kMr. Santosh Shanbhag (Age 46)Chief Financial Officer Ms. Lucy Kate Huntington-BaileyGeneral Counsel & Company SecretaryMs. Suzanne WoodGroup HR DirectorMs. Carol AkinolaHead of Pharmacovigilance & Medical InformationMr. Andrew Hurley (Age 55)Chief Commercial Officer Kate ArmanettiSenior Director of People & CultureMore ExecutivesKey CompetitorsDiurnal GroupLON:DNLCeladon PharmaceuticalsLON:CELProvexisLON:PXSChill Brands GroupLON:CHLLArgent BioPharmaLON:MXCView All Competitors STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 6.70 at the start of the year. Since then, STX shares have decreased by 69.4% and is now trading at GBX 2.05. View the best growth stocks for 2024 here. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN) and Concepta PLC (CPT.L) (CPT). This page (LON:STX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.